Back to discover
Drug

Growth Hormone

Approved · EMA
ClassGrowth hormone receptor agonistEmerging researchLate-stage developmentRising momentum
Also known as Genotropin, Growth hormone (human), Human growth hormone, Humatrope+20 more

Genotropin, Growth hormone (human), Human growth hormone, Humatrope, Norditropin, Nutropin, Nutropin Depot, Omnitrope, SOMATROPIN, Saizen, Serostim, Somatotropin, Somatotropin (human), Somatotropin human, Somatotropin human growth hormone, Somatropina, Tev-tropin, Zomacton, Zorbtive, hGH, rhGH, Recombinant human growth hormone, Somatropin (Recombinant rhGH), Somatropin recombinant.

24
Research papers
18
Active clinical trials
Growth hormone receptor
Primary target
2
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Growth Hormone Replacement Therapy in Veterans With Gulf War Illness and Adult Growth Hormone Deficiency

Clinical trial2026-05-08Results expected Q4 2026 · ClinicalTrials.gov

Low-dose Growth Hormone for the Treatment of Gastroparesis

Clinical trial2026-04-16Results expected Q4 2027 · ClinicalTrials.gov

Approval: Omnitrope (EMA)

Regulatory2006-04-12EMA

Approval: NutropinAq (EMA)

Regulatory2001-02-15EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Growth Hormone
Aliases & brands
GenotropinGrowth hormone (human)Human growth hormoneHumatropeNorditropinNutropinNutropin DepotOmnitropeSOMATROPINSaizenSerostimSomatotropinSomatotropin (human)Somatotropin humanSomatotropin human growth hormoneSomatropinaTev-tropinZomactonZorbtivehGHrhGHRecombinant human growth hormoneSomatropin (Recombinant rhGH)Somatropin recombinant
RxNorm CUI
61148
ChEMBL ID
CHEMBL1201621
ATC codes
H01AC01
UNII
NQX9KB6PCL
Primary mechanism
Growth hormone receptor agonist
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

AGONISTGrowth hormone receptor agonist

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2001-02-15
Latest approval
2006-04-12
Authorities
EMA
Total events
2
emaEuropean Medicines Agency· 2 events
2006-04-12Approval
Approval: Omnitrope (EMA)
Indication: Infants, children and adolescents Growth disturbance due to insufficient secretion of growth hormone (GH). Growth disturbance associated with Turner syndrome. Growth disturbanceShow full indication

Infants, children and adolescents Growth disturbance due to insufficient secretion of growth hormone (GH). Growth disturbance associated with Turner syndrome. Growth disturbance associated with chronic renal insufficiency. Growth disturbance (current height standard-deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children / adolescents born small for gestational age (SGA), with a birth weight and / or length below -2 standard deviations (SDs), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by four years of age or later. Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing. Adults Replacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (SDS < -2) who may be considered for one test. The cut-off point of the dynamic test should be strict.

Evidence ↗
2001-02-15Approval
Approval: NutropinAq (EMA)
Indication: Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion. Long-term treatment of growth failure associated with Turner syndrome.Show full indication

Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion. Long-term treatment of growth failure associated with Turner syndrome. Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology. Growth hormone deficiency should be confirmed appropriately prior to treatment.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

182 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
182
registered trials across all phases
LATEST COMPLETION 2025
18
Active studies
16
Recruiting
123
Late-stage (III+)
119
Completed
45
Discontinued
PHASE DISTRIBUTIONn = 182
Early Phase 14Phase 113Phase 1 / 26Phase 236Phase 2 / 37Phase 356Phase 433Phase N / A27

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

24 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
19992024
Most influential
Recent papers
Major research themes8
Growth Hormone5Human Growth Hormone5Body Height2Insulin Resistance2Quality of Life2Acromegaly1Aging1Blood Glucose1
Journals, researchers & institutions
Top journals
  • The Journal of clinical endocrinology and metabolism6
  • Frontiers in endocrinology4
  • Endocrine journal2
  • Hormone research in paediatrics2
  • Advanced healthcare materials1
  • Clinical and translational science1
Leading researchers
  • Yokoya S4
  • de Muinck Keizer-Schrama SM3
  • Drop SL3
  • Gunnell L3
  • Horikawa R3
  • Klibanski A3
  • Miller KK3
  • Sas TC3
Leading institutions
free-text, unnormalised
  • Sophia Children's Hospital3
  • Hamamatsu University School of Medicine2
  • Massachusetts General Hospital and Harvard Medical School2
  • National Center for Child Health and Development2
  • Osaka University Graduate School of Medicine2
  • Research Institute2

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

6 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 7 of the same disease areas as Growth Hormone in the shared literature.

7 shared diseases2 shared papers

Studied across 6 of the same disease areas as Growth Hormone in the shared literature.

6 shared diseases2 shared papers

Studied across 6 of the same disease areas as Growth Hormone in the shared literature.

6 shared diseases1 shared paper

Studied across 6 of the same disease areas as Growth Hormone in the shared literature.

6 shared diseases1 shared paper

Studied across 5 of the same disease areas as Growth Hormone in the shared literature.

5 shared diseases1 shared paper

Studied across 3 of the same disease areas as Growth Hormone in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.